Clinical trials: Viral Pneumonia
COVID-19
Effect of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Best Standard of Care for the Treatment of Hospitalized COVID-19 Patients and Continued Treatment Following Discharge
The study is a prospective, pilot study aimed to test the safety of Tumor Treating Fields (TTFields) concomitant with best standard of care, for the treatment of hospitalized COVID-19 patients and continued treatment after…
- Trial name
- NCT04953234
- Testing
- NovoTTF-100L
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- NovoCure GmbH
Coronavirus
Behavior, Environment And Treatments for Covid-19
Background: During the current COVID-19 pandemic there is urgent need for information about the natural history of the infection in non-hospitalized patients, including the severity and duration of symptoms, and outcome from…
- Trial name
- BEAT19 (NCT04321811)
- Testing
- Observation of patients with known, suspected, or at risk for COVID-19 infection
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- xCures
SARS-CoV-2, Influenza A
POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.
This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 Ag Ultra test in detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and LumiraDx SARS-CoV-2 \& Flu A/B…
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, COVID-19
- Trial name
- PURSUE (NCT05728970)
- Testing
- LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B
- Where
- 10 sites in United States
- Volunteers
- 716 people, healthy volunteers welcome
- Sponsor
- LumiraDx UK Limited
Covid19
Retrospective Study of ImmunoFormulation for COVID-19
Multicentre, retrospective, observational study to describe the course of SARS-CoV-2 disease in patients treated or not with IMUNO TF ® and a combination of nutraceuticals and who have tested positive in a COVID-19 diagnostic…
- Trial name
- NCT04666753
- Testing
- ImmunoFormulation
- Where
- 2 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fagron Iberica S.A.U.
COVID-19
A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19
The study is comprised of two parts: safety evaluation part (Phase I/II) and the pivotal study (Phase III) to evaluate the efficacy and safety of the combination of SCTA01 \& SCTA01C compared to placebo in addition to Standard of…
- Trial name
- NCT05156645
- Testing
- SCTA01 and SCTA01C
- Sponsor
- Sinocelltech Ltd.
SARS-CoV-2
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children as intramuscular (IM) injection in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and a third dose or an…
- Trial name
- NCT04796896
- Testing
- mRNA-1273, mRNA-1273.214
- Where
- 91 sites in United States, Canada
- Volunteers
- 11,942 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Biological Availability, Healthy Participants
Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants
The purpose of this study is to estimate the relative bioavailability of nirmatrelvir/ritonavir of 4 different FDC tablet formulations relative to the commercial tablet formulation under fasted conditions in healthy adult…
- Trial name
- NCT05525910
- Testing
- Nirmatrelvir/ ritonavir, Nirmatrelvir/ritonavir
- Where
- United States
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Pfizer
COVID-19, ARDS, Human
Inhaled Iloprost for Suspected COVID-19 Respiratory Failure
Acute respiratory distress syndrome (ARDS) is a type of respiratory failure characterized by the rapid onset of widespread inflammation in the lungs.
- Conditions
- COVID-19, ARDS, Human, Hypoxemic Respiratory Failure
- Trial name
- ILOCOVID (NCT04445246)
- Testing
- Inhaled ILOPROST
- Where
- Qatar
- Volunteers
- 40 people
- Sponsor
- Hamad Medical Corporation
Covid19
Epidemiological Study of the COVID-2019 in Participating Organizations.
Exhaustive, cross-sectional, non-interventional, multicenter retrospective epidemiological study, case study aimed to determine the relationship between the systematic use of prophylactics to prevent SARS, including COVID-2019…
- Trial name
- NCT05043142
- Testing
- ELISA test for the antibodies to COVID-2019.
- Where
- 7 sites in Ukraine
- Volunteers
- 3,632 people, healthy volunteers welcome
- Sponsor
- Yuria-Pharm
Cognitive Decline, Cognitive Dysfunction
Open-label, Post-marketing, Prospective Study to Assess Impact of COVID-19 on Cognitive Function in Patients
The objective of this study is to compare the impact of the coronavirus disease (SARS-CoV-2, or COVID-19) on cognitive function in the population of patients who have been diagnosed, treated and recovered from the COVID-19…
- Conditions
- Cognitive Decline, Cognitive Dysfunction, Brain Health, Post CoV-2 Syndrome
- Trial name
- COVID19 (NCT04950673)
- Testing
- Cognivue
- Where
- 4 sites in United States
- Volunteers
- 1,000 people, healthy volunteers welcome
- Sponsor
- Cognivue, Inc.
COVID-19
An Observational Study to Describe EVUSHELD™ (Tixagevimab/Cilgavimab) Pre-exposure Prophylaxis in Real-world Setting in Japan
This is an observational, cohort study that will use secondary data to describe the baseline demographics and clinical characteristics in patients who received EVUSHELD as PrEP against SARS-CoV-2 infection/COVID-19 in Japan.
- Trial name
- Evusheld DBR (NCT06156982)
- Testing
- Evusheld
- Where
- Japan
- Volunteers
- 397 people
- Sponsor
- AstraZeneca
COVID-19, HIV Infections
Immunogenicity and Safety of an Inactivated COVID-19 Vaccine in People With HIV Infected
Evaluation of immunogenicity and safety of the subjects infected with HIV to receive the schedule of two doses inactivated COVID-19 vaccine with the interval of 21 days .
- Trial name
- NCT05075070
- Testing
- Inactivated COVID-19 vaccine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- China National Biotec Group Company Limited
Long COVID
Study of Xiflam™ Treatment in Patients Post COVID-19 Infection Suffering From What is Known as Long COVID (LC)
The primary objective of this study is to evaluate the safety and efficacy of Xiflam versus Placebo in patients who present with signs and symptoms of Long COVID.
- Trial name
- NCT06437223
- Testing
- Tonabersat
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Inflammx Therapeutics Inc
COVID-19, SARS-CoV-2
Study of Sargramostim in Patients With COVID-19
The purpose of this research is to find out if a drug (sargramostim) also known as Leukine® could help patient recover faster from COVID-19.
- Trial name
- iLeukPulm (NCT04411680)
- Testing
- Sargramostim, Standard of care
- Where
- 11 sites in United States
- Volunteers
- 123 people
- Sponsor
- Partner Therapeutics, Inc.
COVID-19, Yellow Fever
A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19
This is a placebo-controlled, randomized, double-blind study to evaluate the pharmacokinetics, safety and antiviral activity of galidesivir in subjects with yellow fever (YF) or COVID-19.
- Trial name
- NCT03891420
- Testing
- Galidesivir
- Where
- 5 sites in Brazil
- Volunteers
- 24 people
- Sponsor
- BioCryst Pharmaceuticals
SARS-CoV-2 Infection
A Study of SARS-CoV-2 mRNA Vaccine (SYS6006) in Chinese Healthy Participants Aged 18 Years or More
This is a phase 2, randomized, observer-blinded, placebo-controlled clinical study to evaluate the immunogenicity and safety of SARS-CoV-2 mRNA Vaccine (SYS6006）in healthy participants aged 18 or more.
- Trial name
- NCT05439824
- Testing
- SYS6006 20 μg, SYS6006 30 μg
- Where
- 2 sites in China
- Volunteers
- 450 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Covid19
A Clinical Study Evaluating Inhaled Aviptadil on COVID-19
This study is a multicenter, prospective, placebo-controlled, comparative, randomized, double-blind local phase II clinical trial. Duration of study is 18 months.
- Trial name
- HOPE (NCT04844580)
- Testing
- Inhaled Aviptadil
- Where
- 9 sites in Turkey (Türkiye)
- Volunteers
- 80 people
- Sponsor
- Centurion Pharma
COVID-19
MP1032 Treatment in Patients With Moderate to Severe COVID-19
The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to severe coronavirus disease 2019 (COVID-19).
- Trial name
- NCT04932941
- Testing
- MP1032
- Where
- 31 sites in United States, Bulgaria and 5 more
- Volunteers
- 132 people
- Sponsor
- MetrioPharm AG
COVID-19, SARS-CoV-2 Infection
A Study to Evaluate the Immunogenicity and Safety of a Recombinant Protein COVID-19 Vaccine SCTV01E-1 in Population Aged Above 18 Years
The study is a randomized, double-blind Phase II study. It will evaluate the immunogenicity and safety of SCTV01E-1. Approximately 400 participants aged 18 years and older will be enrolled in this study.
- Trial name
- NCT05522829
- Testing
- SCTV01E-1 on D0, SCTV01E-1 on D28, SCTV01E-1 on D150
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Sinocelltech Ltd.
Influenza Type A, Influenza Type B
Clinical Feasibility of the BinaxNOW™ COVID-19/Flu A&B Combo in the Southern Hemisphere
The study is designed as a clinical feasibility, to investigate the positive and negative percent agreement (PPA and NPA) of the BinaxNOW™ COVID-19/Flu A\&B Combo against a highly sensitive PCR method(s) in symptomatic patients…
- Conditions
- Influenza Type A, Influenza Type B, COVID-19
- Trial name
- NCT06928129
- Testing
- BinaxNOW™ COVID-19/Flu A&B Combo Self-Test
- Volunteers
- 700 people
- Sponsor
- Abbott Rapid Dx
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.